Johnson & Johnson

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 4,567 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Johnson & Johnson has no founder or dual-class structure; it is a widely held, single-class company with no controlling shareholder. The individual insider positions listed (Duato, Taubert, Wolk, Schmid) are the Named Executive Officers with the largest holdings, not a controlling stake: even the full 21-person group of directors and executive officers holds under 0.2% of shares outstanding.
• The register's institutional rows (Vanguard, BlackRock, State Street, JPMorgan, Geode, Morgan Stanley) are taken from the pre-built 13F-derived register at data/registers/JNJ.json (period 31-MAR-2026), not re-derived. Only a curated subset of that register's 40 rows is reproduced here, per the brief.
• JNJ's own Q2 2026 10-Q reports total equity investments of $803m with readily determinable fair value and $832m without readily determinable fair value (non-marketable, mostly private JJDC venture stakes), but does not itemize either bucket by issuer. The 15 holdings listed above are the itemized, readily-determinable-value slice: they came instead from JNJ's own Form 13F-HR (period 30 Jun 2026), which totals $798,650,757 across those 15 public issuers, closely reconciling with the 10-Q's $803m readily-determinable-value figure (the small gap is normal 13F/10-Q valuation-date and methodology differences).
• All 15 holdings are managed by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), JNJ's corporate venture capital arm; JJDC's public positions are reported on JNJ's own 13F-HR rather than a separate JJDC filer CIK.
• Legend Biotech (LEGN) is a JJDC equity stake, distinct from JNJ's separate, larger commercial collaboration and cost-sharing agreement with Legend's Carvykti cell therapy; only the equity stake is captured here as a holding.